Journal of Virology · 2009 · 40 citations · 55 references
MedicineImmunologyOncologyCancer ImmunologyMolecular VirologyTumor ImmunologyCancer ImmunotherapyCancer VaccinesOncogenic VirusesOncolytic Virus ImmunotherapyOncolytic Virus TherapyAdenoviral VectorsAdenovirus VectorsGranulocyte Colony-stimulating Factor AdministrationMurine ModelsOncolytic Viral VectorsReplication-competent VectorsSyngeneic Tumor ModelsTransgene Expression
Oncolytic adenoviral vectors that express immunostimulatory transgenes are currently being evaluated in clinic. Preclinical testing of these vectors has thus far been limited to immunodeficient xenograft tumor models since human adenoviruses do not replicate effectively in murine tumor cells. The effect of the immunostimulatory transgene on overall virus potency can therefore not be readily assessed in these models. Here, a model is described that allows the effective testing of mouse armed oncolytic adenovirus (MAV) vectors in immunocompetent syngeneic tumor models. These studies demonstrate that the MAV vectors have a high level of cytotoxicity in a wide range of murine tumor cells. The murine oncolytic viruses were successfully armed with murine granulocyte-macrophage colony-stimulating factor (mGM-CSF) by a novel method which resulted in vectors with a high level of tumor-specific transgene expression. The mGM-CSF-armed MAV vectors showed an improved level of antitumor potency and induced a systemic antitumor immune response that was greater than that induced by unarmed parental vectors in immunocompetent syngeneic tumor models. Thus, the oncolytic MAV-1 system described here provides a murine homolog model for the testing of murine armed oncolytic adenovirus vectors in immunocompetent animals. The model allows evaluation of the impact of virus replication and the host immune response on overall virus potency and enables the generation of translational data that will be important for guiding the clinical development of these viruses.
55
Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
Thomas J. Wickham, Patricia Mathias, David A. Cheresh et al. · Cell · 1993 · 2.2K citations
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Juàn Fueyo, Candelaria Gomez‐Manzano, Ramón Alemany et al. · Oncogene · 2000 · 772 citations
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Carla Heise, Terry Hermiston, Leisa Johnson et al. · Nature Medicine · 2000 · 585 citations
Medicine, Oncology, Pharmacology +12